Alteogen challenges to KRW 1.8 trillion acromegaly treatment market with Severance Hospital

Published: 2017-12-27 16:19:39

Updated: 2017-12-27 16:47:24

Alteogen(Soon-Jae Park), a company developing antibody biobetters, announced on the 22nd that the company has signed a co-development agreement of an acromegaly treatment using NexP™-based growth hormone receptors with Severance Hospital Pituitary Gland Tumor Center(Professor Eun-Jik Lee, Cheol-Ryong Koo).

According to Alteogen, they are expected to conduct studies to develop a new substance ...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.